Abbie Celniker Sells 10,031 Shares of Eleven Biotherapeutics Inc. (EBIO) Stock
Eleven Biotherapeutics Inc. (NASDAQ:EBIO) Director Abbie Celniker sold 10,031 shares of the stock in a transaction on Wednesday, September 28th. The shares were sold at an average price of $3.00, for a total value of $30,093.00. Following the completion of the transaction, the director now directly owns 409,915 shares of the company’s stock, valued at $1,229,745. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink.
Eleven Biotherapeutics Inc. (NASDAQ:EBIO) opened at 2.80 on Friday. The company has a 50-day moving average price of $4.23 and a 200 day moving average price of $2.31. The firm’s market capitalization is $43.10 million. Eleven Biotherapeutics Inc. has a 1-year low of $0.25 and a 1-year high of $5.97.
Eleven Biotherapeutics (NASDAQ:EBIO) last issued its quarterly earnings results on Friday, August 12th. The biopharmaceutical company reported ($0.33) EPS for the quarter. Eleven Biotherapeutics had a negative net margin of 2,995.34% and a negative return on equity of 207.40%. Analysts expect that Eleven Biotherapeutics Inc. will post ($1.75) earnings per share for the current fiscal year.
A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Bank of New York Mellon Corp increased its position in Eleven Biotherapeutics by 13.2% in the second quarter. Bank of New York Mellon Corp now owns 67,483 shares of the biopharmaceutical company’s stock worth $112,000 after buying an additional 7,846 shares in the last quarter. Boxer Capital LLC purchased a new position in Eleven Biotherapeutics during the second quarter worth approximately $1,670,000. Sabby Management LLC increased its position in Eleven Biotherapeutics by 525.6% in the first quarter. Sabby Management LLC now owns 1,213,984 shares of the biopharmaceutical company’s stock worth $387,000 after buying an additional 1,019,943 shares in the last quarter. Flagship Ventures Fund IV General Partner LLC purchased a new position in Eleven Biotherapeutics during the second quarter worth approximately $2,464,000. Finally, Flagship Ventures Fund IV L.P. purchased a new position in Eleven Biotherapeutics during the first quarter worth approximately $469,000. 34.32% of the stock is owned by hedge funds and other institutional investors.
About Eleven Biotherapeutics
Eleven Biotherapeutics, Inc is a clinical-stage biopharmaceutical company. The Company through AMP-Rx, a protein engineering platform, is engaged in the discovery and development of protein therapeutics to treat diseases of the eye. The Company designs, engineers and generates a pipeline of protein therapeutic candidates that target cytokines, which are central to diseases of the eye.
Receive News & Stock Ratings for Eleven Biotherapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eleven Biotherapeutics Inc. and related stocks with our FREE daily email newsletter.